Mar 23, 2024
The 8th Annual FTD Forum
SABPA FTD annually brings together the latest in groundbreaking research, cutting-edge drugs, and industry trends within the biopharma sector. The event's broad spectrum of topics provides a platform for local biotech companies to engage in vibrant discussions and valuable networking opportunities. The forthcoming 8th FTD Conference is set to shine a spotlight on three revolutionary domains in the field of metabolism disease and oncology: Glucagon-like peptide-1 (GLP-1), Antibody-Drug Conjugates (ADC), and Minimal Residual Disease (MRD), each representing the forefront of innovations in therapeutics and diagnostics.
This event is over.
Date and Time
March 23, 2024, 8:00 am - 5:00 pmLocation
Hilton San Diego/Del Mar 15575 Jimmy Durante Boulevard Del Mar, CA 92014Refund Policy
You may cancel your registration up to 3 days before the event. Regrettably, we will not be able to refund your registration fee, but you may request a credit to be used towards payment for our future events or membership enrollment/renewal. Please email your request or questions to noreply@sabpa.org.
About this Event
Registration timeline:
Early registration (by February 29, 2024) $60/30, regular/student
Advance Registration (From March 1st, 2024) $80/40, regular/student
On-site Registration: $100/50, regular/student
Highlighted topics:
- We are thrilled to announce Dr. Lotte Bjerre Knudsen, Chief Scientific Advisor at Novo Nordisk, as our keynote speaker for this session. Dr. Knudsen will be presenting on the topic “GLP-1 Receptor Agonists, from Diabetes and Obesity, to Cardiovascular Disease”.
- Dr. Shawn Shao-Hui Zhang, CSO and General Manager China at Ambrx Inc, will present to us “Building Highly Stable and Efficacious ADCs with Expanded Genetic Code Enabled Site-Specific Conjugation Technology”, which will be followed by a panel discussion among leading ADC industry leaders.
- The emergence of Minimal Residual Disease (MRD) has revolutionized cancer therapeutics, offering a strategic approach to detecting and targeting residual cancer cells that may linger post-treatment. MRD assessments provide invaluable insights into disease progression and treatment response. Join us as Dr. Tyler Stewart, Assistant Professor of Medicine at the University of California San Diego, unveils "CtDNA to Optimize Cancer Care: Embracing the Future".
Highlighted speakers:
- Lotte Bjerre Knudsen, Chief Scientific Advisor, Novo Nordisk
- Shawn Shao-Hui Zhang, CSO and General Manager China, Ambrx Inc
- William C. Roell, Director – Insulin Discovery/Incretin Discovery, Eli Lilly and Company
- W. Michael Flanagan, Chief Scientific and Technical Officer, Avidity Biosciences
- Alan Jiang, Chief Strategy Officer, XtalPi Inc
- Mark Fineman, Chief Development Officer, Glyscend Therapeutics
- Tyler Stewart, Assistant Professor of Medicine – Genitourinary Malignancies, UCSD
In addition to our compelling lineup of presentations, the 2024 SABPA FTD Conference will feature a dynamic Poster Session, adding a unique dimension to the event.
We extend an invitation to postdocs, graduate students, and research professionals from local institutes and universities to showcase their innovative research, fostering collaborations and sharing discoveries. Reviewers from our industry will offer valuable insights and personalized, face-to-face feedback to presenters on their posters, enhancing the benefits derived from this session and facilitating a seamless transition from academia to industry. As a small token of appreciation, conference registration fee will be waived for poster presenters.
Submit your poster abstract: https://docs.google.com/forms/d/e/1FAIpQLSdqgzPuuUAmWqMHePb0V0Den8wGoG-_IOpPOcnMl05A5Z7Uxg/viewform?usp=sf_link
Poster flyer link: https://drive.google.com/file/d/1KMtFLlU867OHwjQcf2Ulxxd1Gk5aGmll/view?usp=sharing
Current Posters link: https://drive.google.com/open?id=1XKxl3fQG5BLyvlGHFHgkig89djkLYPxO&usp=drive_fs
Below is the event flyer:
